Company* |
University/ |
Type Of Agreement | Product Area | Details (Date) |
Adherex |
National Cancer Institute |
Clinical trial agreement |
The NCI is sponsoring studies of Adherex's ADH-1 (Exherin) |
The agent targets N-cadherin, a protein present on certain tumor cells (4/5) |
AEterna |
University |
Agreement |
Deal for preclinical research on the role of ghrelin in the development of obesity |
The three-year project has an initial budget of C$1.2M (US$1M) (5/3) |
Affymetrix |
Korea's National Institute of Health |
Agreement |
The Korean NIH will use Affymetrix GeneChip technology in genomic studies |
The institute and its collaborators are working in the areas of diabetes, hypertension, asthma and metabolic syndrome (3/8) |
Alnylam |
CBR Institute for Biomedical Research |
License agreement |
Alnylam got rights to technology that allows for targeted delivery of RNAi agents |
The CBR Institute is an affiliate of Harvard Medical School; terms of the deal were not disclosed (5/9) |
Alnylam |
U.S. Army Medical Research Institute of Infectious Diseases |
CRADA |
Deal to discover RNAi therapeutics targeting viral organisms, fever viruses including hemorrhagic |
Terms of the agreement were not disclosed (4/12) |
Alnylam |
Massachusetts Institute of Technology |
Agreement |
Alnylam got access to liposome technology |
Alnylam has an option to license the technology, which has shown promise for delivering RNAi therapeutics (3/27) |
Avecia Inc.* |
Various entities |
Partnership |
Avecia is taking a lead role in a program to establish bioprocessing technology for tissue engineering |
Partners in the effort include Durham University, the Blond McIndoe Centre and Smith & Nephew; the UK government is providing funding support (4/24) |
BioSystems |
Northeastern University |
License agreement |
BioSystems licensed rights to a biomarker discovery and development platform |
BioSystems gets exclusive, worldwide rights to the monoclonal antibody-based technology; terms were not disclosed (3/10) |
Callisto |
University of Texas M.D. Anderson Cancer Center |
Research agreement |
M.D. Anderson will support development of the company's Degrasyn class of cancer compounds |
Callisto is sponsoring research for two years at the cancer center, which previously licensed the compounds to Callisto (5/10) |
Cel-Sci Corp. |
Naval Medical Research Center of the U.S. Navy |
CRADA |
They extended a deal to evaluate CEL-SCI's CEL-1000 in malaria applications |
They are evaluating the small- peptide agent against several species of malaria and as an adjuvant with various malaria vaccines (4/20) |
Ceragenix |
Johns Hopkins University School of Medicine |
Research agreement |
Hopkins researchers will evaluate an anti- microbial wound dressing from Ceragenix |
The Johns Hopkins Burn Center will evaluate the product in animal models of certain infections (5/10) |
Chimerix Inc.* |
U.S. Army Medical Research Institute of Infectious Diseases |
CRADA |
Deal to to evaluate Chimerix's smallpox therapeutic, CMX001, in animal models |
Chimerix will test CMX001 and potentially other candidates in USAMRIID's animal models of smallpox and monkey pox infection (4/18) |
Circadian |
Ludwig Institute for Cancer Research (Germany) and the University of Helsinki |
Venture |
The parties formed a company, Vegenics Ltd., to develop and sell vascular endothelial growth factors in cancer indications |
Vegenics is 50% owned by Circadian and 50% by LICR and university affiliate Licentia Ltd.; Circadian is providing an initial equity investment in Vegenics (5/1) |
Clinical Data |
Institute for Genome Sciences & Policy at Duke University |
Agreement |
IGSP is getting access to studies on genetic variants associated with the effect of statins on lipid parameters |
Clinical Data will get the first right to negotiate a commercial license to resulting findings under the five-year deal (5/12) |
Cronos |
Cancer Research Technology Ltd. (UK) |
Collaboration |
To develop a cancer therapy based on Cronos' GeneICE platformtechnology |
GeneICE is an epigenetic gene regulation technology; they will work on inhibiting expression of an undisclosed gene target (3/27) |
CytoGenix |
University of Texas Medical Branch at Galveston |
Research agreement |
Deal for preclinical animal studies of the company's synDNA H5N1 vaccine |
The synthetic synDNA technology is designed to produce millions of doses of a DNA vaccinewithin a few months (5/16) |
DNAPrint |
Massachusetts College of Pharmacy and Health Sciences |
Sponsored research agreement |
Deal to study analogues of Ritalin for treating various conditions |
The goal is to developtest/drug |
Dyadic |
The Scripps Research Institute |
Agreement |
Deal to provide a complete annotation of the genome of a fungal organism |
Scripps will help annotate the Chrysosporium lucknowense organism from Dyadic; terms were not disclosed (3/31) |
Edison |
University of Bologna (Italy) and Columbia University Medical Center |
Collaboration |
To discover treatments for treating inherited mitochondrial diseases |
They plan to identify new classes of compounds targeting diseases of the eye and brain, as well as molecular targets and clinical biomarkers (3/16) |
EvoGenix Ltd. |
University of Massachusetts Medical School |
License agreement |
Evogenix got rights to an anticancer hamster antibody, DMF10 |
UMMS is entitled to an upfront payment, as well as potential milestone payments and a small royalty on any resulting sales (4/10) |
Evotec AG |
University of Cincinnati and Cincinnati Children's Hospital Medical Center |
Purchase agreement |
Deal for the purchase of Evotec's ultra-high-throughput screening system |
The $2.8M system will be housed at UC's Genome Research Institute and eventually will be used by researchers throughout Ohio (4/4) |
4SC AG |
University of Münster (Germany) |
Collaboration |
Deal to develop an agent for treating influenza virus infections |
4SC will work with the university's Institute of Molecular Virology in the effort; terms were not disclosed (4/12) |
Gen-Probe |
University of Michigan |
License agreement |
Gen-Probe got rights to develop diagnostic tests based on genetic translocations |
UM gets $0.5M up front, research funding, and potential milestone and royalty payments; the technology has been shown to be highly specific for prostate cancer tissue (5/1) |
Geron Corp. |
University of Oxford (UK) |
License and research agreements |
Geron licensed rights to technology on dendritic cells derived from human embryonic stem cells |
Geron also will fund work at the university to further develop the technology (3/27) |
HaptoGuard |
University of Calgary (Canada) |
License agreement |
HaptoGuard got world- wide rights to a family of compounds directed against cardiovascular disease |
The compounds are glutathione peroxidase mimetics; terms of the exclusive deal were not disclosed (5/9) |
Illumina Inc. |
Cancer Research UK |
Services agreement |
Illumina will provide genotyping services on prostate cancer patients and controls |
The deal is valued at nearly $7M; under a previous deal, Illumina is providing genotyping in the area of colorectal cancer for Cancer Research UK (4/11) |
ImmPORT |
Foundation for Innovative New Diagnostics (Switzerland) and the Public Health Research Institute |
Collaboration |
Deal to to identify antigens useful for the diagnosis of tuberculosis |
ImmPORT's whole-proteome microarray chip technology platform will be used in the effort to develop a fast and affordable diagnostic (5/15) |
Incitive Ltd. |
Queensland Institute of Medical Research (Australia) |
Agreement |
Deal to evaluate Incitive's CCS product for inflammation and autoimmune diseases |
The deal covers validation and preclinical evaluation of the agent against various disorders; terms were not disclosed (4/20) |
Invitrogen |
NIH Chemical Genomics Center |
Collaboration |
Deal to identify small molecules that modulate signaling pathways associated with disease pathophysiology |
The NCGC will use Invitrogen's cell lines and beta-lactamase reporter gene technology in the effort; data will be deposited in the NIH's PubChem database (3/6) |
Miraculins Inc. |
Duke University Medical Center |
Agreement |
Deal to further develop Miraculins' prostate cancer diagnosticproject |
Duke is providing research capa- bilities and its patient network to the effort; terms were not dis-closed (4/10) |
Mymetics Corp. (Switzerland; PK:MYMX) |
National Institutes of Health |
Agreement |
The NIH agreed to test the company's HIV-AIDS mucosal prophylactic vaccine candidate |
The preclinical study will test the vaccine in a nonhuman primate model, in parallel to an ongoing preclinical trial (3/9) |
NephroGenex |
Vanderbilt University |
License agreement |
NephroGenex got rights covering the use of Pyridorin as a treatment for acute renal failure |
Terms of the deal were not dis- closed (5/10) |
Norwood |
Australian Stem Cell Centre and Monash University (Australia) |
Research agreement |
To develop a technology platform combining immune system research with stem cell know-how |
The focus is on controlling the immune system to minimize rejection of stem cell therapies; Norwood and the ASCC would jointly commercialize resulting technology (3/21) |
Open |
CIC bioGUNE (Spain) |
Agreement |
CIC joined OBI's Open Access RNAi Program |
Through the deal CIC purchased OBI's whole- enome human retroviral shRNAmir library (5/11) |
Open |
Northwestern University |
Agreement |
Northwestern joined OBI's Open Access RNAi Program |
The program at Northwestern includes shRNAmir lentiviral libraries targeting the human and mouse genomes (3/8) |
Paratek |
Families of Spinal Muscular Atrophy |
Collaboration |
Deal to develop a small- molecule candidate for treating spinal muscular atrophy |
They will focus on optimizing and advancing into the clinic a Paratek compound from the tetracycline class (5/17) |
Pharminox |
Cancer Research Technology Ltd. (UK) |
License agreement |
Pharminox got rights to an oncology program focused on targeting telomere signaling |
Pharminox has a 12-month option to license exclusive, worldwide rights; terms were not disclosed (4/19) |
Phoenix |
Christus Stehlin Foundation |
Collaboration |
Deal to investigate a Phoenix drug against melanoma |
Phoenix is developing botanical extracts in collaboration with the University of Texas M.D. Anderson Cancer Center (5/3) |
PhytoMedical |
Iowa State University and the USDA's Agricultural Research Service |
Extended CRADA |
New deal designed to accelerate plans to develop a compound for treating Type II diabetes |
The research is focused on synthesizing certain insulin-enhancing or mimetic polyphenolic compounds designed to improve insulin function (3/21) |
Primagen |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Primagen expanded its rights to the CD133 diagnostic biomarker |
Its worldwide license to the bio- marker was expanded to include the cardiovascular field; terms were not disclosed (4/25) |
Primagen |
European Union |
Agreement |
Primagen was chosen to participate in the EU- funded GRACE project on combating antibiotic resistance |
Primagen will screen samples of patients with respiratory tract infections to identify novel viruses, along with the Leiden University Medical Center (3/28) |
Reata |
Dartmouth College and the M.D. Anderson Cancer Center |
License agreement |
Reata got exclusive rights to a new class of anti- inflammatory compounds |
The compounds, tricyclic bisenones, are activators of the transcription factor Nrf2; terms were not disclosed (4/17) |
Santaris |
University of Copenhagen (Denmark) |
Agreement |
They formed a microRNA research consortium |
The work focused on developing microRNAs as drug targets is being funded in part by the Danish Advanced Technology Foundation (5/1) |
Serologicals |
Australian Stem Cell Centre |
Agreement |
A Serologicals subsidiary got rights to stem cell reagents developed at ASCC |
Chemicon International Inc. got exclusive rights to commercialize and distribute the reagents to scientists worldwide (4/21) |
Shanghai |
PATH Malaria Vaccine Initiative |
Agreement |
PATH will support development of a pediatric malaria vaccine against Plasmodium falciparum |
The deal will allow for improvements in the manufacturing process and lead to a safety evaluation of the vaccine candidate, PfCP2.9 (3/15) |
Sirna |
University of Massachusetts Medical School |
License agreement |
Sirna got rights to patents covering microRNA technology for the modulation of gene expression |
Sirna got exclusive rights to the Zamore miRNA patents for all uses; terms of the deal were not disclosed (5/10) |
SpeciGen Inc.* |
Montanta State University |
License agreement |
SpeciGen got rights to protein cage-based nanotechnologies |
The technology will be used for targeted delivery of diagnostic and therapeutic agents; SpeciGen also will sponsor research at MSU (4/28) |
Sunesis |
University of California at San Francisco |
Research and license agreement |
UCSF got rights to use Sunesis' fragment- based Tethering drug discovery technology |
Sunesis gets exclusive rights to any resulting improvements to the technology or fragment libraries, and would have first rights to license resulting small-molecule drug candidates (4/7) |
Syntarga BV* |
Georg-August University (Germany) |
License agreement |
Syntarga got exclusive, worldwide rights to anticancer agents |
Syntarga will incorporate the alkylating agents in antibody- drug and other conjugates; terms were not disclosed (3/14) |
Target |
University of Texas M.D. Anderson Cancer Center |
Collaboration |
To develop a new generation of cancer diagnostic assays |
Target Discovery will use its mass defect technology to validate protein biomarkers from samples provided by M.D. Anderson (4/20) |
Target |
Eastern Virginia Medical School |
Collaboration |
To develop clinical assays that will help guide treatment of prostate cancer |
They plan to validate protein iso- form biomarkers and integrate them into Target Discovery's Isonostics clinical platform (3/21) |
TiGenix Inc. |
Hospital for Special Surgery |
Collaboration |
The hospital will help develop TiGenix's lead cartilage repair product |
The product, ChondroCelect, is a cell-based therapy designed for the repair of cartilage defects of the knee (3/28) |
Vaxon Biotech* |
Institut Pasteur(France) |
License deal and collaboration |
Deal to develop new vaccine products and animal transgenic models |
Vaxon intends to develop products covering major HLA super-families for treating cancers; terms were not disclosed (4/3) |
Vertex |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration |
Deal to to accelerate development of VX-770, an oral agent being developed to treat CF |
CFFT will pay Vertex about $13.3M in development support through 2007; Vertex retains worldwide rights (3/23) |
VM Discovery |
Fred Hutchinson Cancer Research Center |
Collaboration |
To jointly pursue a discovery program for cancer drugs |
VMD will use its design and optimization technology to generate lead compounds, while the center will contribute its expertise; terms were not disclosed (3/31) |
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
CRADA = Cooperative Research and Development Agreement. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadaian Venture Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | ||||
